Travere Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

TVTX Stock

USD 18.75 0.02 0.11%

Travere Therapeutics financial indicator trend analysis is much more than just breaking down Travere Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Travere Therapeutics is a good investment. Please check the relationship between Travere Therapeutics Ev To Free Cash Flow and its Free Cash Flow Yield accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Travere Therapeutics Ev To Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Travere Therapeutics' Ev To Free Cash Flow and Free Cash Flow Yield is -0.35. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Travere Therapeutics, assuming nothing else is changed. The correlation between historical values of Travere Therapeutics' Ev To Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Travere Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Ev To Free Cash Flow i.e., Travere Therapeutics' Ev To Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.35

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Travere Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Travere Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.At this time, Travere Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 234.2 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 113.4 M in 2024.

	2021	2022	2023	2024 (projected)
Research Development	210.3M	235.8M	245.0M	123.1M
Depreciation And Amortization	26.6M	20.7M	38.5M	19.6M

Research Development Depreciation And Amortization

Travere Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Current Assets	Intangible Assets	Short Term Investments	Property Plant And Equipment Gross
Total Assets		0.72	0.84	0.87	0.8	0.54	-0.68	0.6	0.83	0.98	0.92	0.47	0.85	0.82	0.85	0.99	0.2	0.94	0.62	0.2	0.93	0.31	0.68	0.86	0.96	0.6
Short Long Term Debt Total	0.72		0.68	0.78	0.27	0.96	-0.97	0.81	0.52	0.78	0.79	0.48	0.97	0.95	0.97	0.76	-0.05	0.77	0.87	-0.27	0.58	0.65	0.84	0.46	0.84	0.89
Other Current Liab	0.84	0.68		0.87	0.56	0.58	-0.73	0.66	0.57	0.8	0.88	0.45	0.77	0.79	0.79	0.84	0.14	0.94	0.66	0.09	0.79	0.56	0.8	0.68	0.82	0.65
Total Current Liabilities	0.87	0.78	0.87		0.5	0.67	-0.76	0.67	0.63	0.85	0.93	0.43	0.82	0.8	0.86	0.86	0.4	0.95	0.66	0.17	0.8	0.4	0.71	0.71	0.86	0.66
Total Stockholder Equity	0.8	0.27	0.56	0.5		0.06	-0.22	0.34	0.75	0.72	0.57	0.25	0.45	0.48	0.46	0.75	0.28	0.63	0.21	0.49	0.85	0.03	0.4	0.85	0.67	0.2
Net Debt	0.54	0.96	0.58	0.67	0.06		-0.94	0.79	0.26	0.6	0.65	0.43	0.88	0.86	0.88	0.59	-0.1	0.63	0.78	-0.37	0.4	0.71	0.84	0.28	0.71	0.83
Retained Earnings	-0.68	-0.97	-0.73	-0.76	-0.22	-0.94		-0.83	-0.5	-0.74	-0.8	-0.49	-0.93	-0.96	-0.94	-0.73	0.12	-0.78	-0.92	0.33	-0.51	-0.74	-0.86	-0.38	-0.8	-0.95
Accounts Payable	0.6	0.81	0.66	0.67	0.34	0.79	-0.83		0.38	0.63	0.65	0.38	0.77	0.86	0.81	0.62	0.0	0.66	0.66	-0.19	0.51	0.74	0.86	0.43	0.71	0.74
Cash	0.83	0.52	0.57	0.63	0.75	0.26	-0.5	0.38		0.84	0.76	0.34	0.66	0.65	0.65	0.82	0.14	0.74	0.59	0.2	0.76	0.08	0.34	0.73	0.74	0.53
Cash And Short Term Investments	0.98	0.78	0.8	0.85	0.72	0.6	-0.74	0.63	0.84		0.93	0.5	0.88	0.85	0.87	1.0	0.07	0.92	0.7	0.06	0.84	0.33	0.66	0.75	0.98	0.68
Common Stock Total Equity	0.92	0.79	0.88	0.93	0.57	0.65	-0.8	0.65	0.76	0.93		0.46	0.87	0.85	0.88	0.93	0.18	0.96	0.74	0.03	0.8	0.45	0.69	0.72	0.92	0.72
Common Stock Shares Outstanding	0.47	0.48	0.45	0.43	0.25	0.43	-0.49	0.38	0.34	0.5	0.46		0.5	0.5	0.48	0.5	-0.07	0.44	0.49	-0.15	0.34	0.32	0.44	0.26	0.52	0.49
Non Current Liabilities Total	0.85	0.97	0.77	0.82	0.45	0.88	-0.93	0.77	0.66	0.88	0.87	0.5		0.96	0.99	0.87	-0.01	0.86	0.84	-0.15	0.73	0.57	0.83	0.63	0.92	0.84
Other Stockholder Equity	0.82	0.95	0.79	0.8	0.48	0.86	-0.96	0.86	0.65	0.85	0.85	0.5	0.96		0.97	0.84	-0.03	0.85	0.88	-0.15	0.7	0.69	0.9	0.58	0.89	0.91
Total Liab	0.85	0.97	0.79	0.86	0.46	0.88	-0.94	0.81	0.65	0.87	0.88	0.48	0.99	0.97		0.87	0.08	0.88	0.84	-0.09	0.76	0.58	0.86	0.66	0.91	0.85
Total Current Assets	0.99	0.76	0.84	0.86	0.75	0.59	-0.73	0.62	0.82	1.0	0.93	0.5	0.87	0.84	0.87		0.1	0.93	0.68	0.1	0.87	0.35	0.69	0.78	0.98	0.66
Short Term Debt	0.2	-0.05	0.14	0.4	0.28	-0.1	0.12	0.0	0.14	0.07	0.18	-0.07	-0.01	-0.03	0.08	0.1		0.22	-0.14	0.74	0.42	-0.3	0.04	0.5	0.04	-0.14
Common Stock	0.94	0.77	0.94	0.95	0.63	0.63	-0.78	0.66	0.74	0.92	0.96	0.44	0.86	0.85	0.88	0.93	0.22		0.72	0.14	0.86	0.45	0.75	0.76	0.92	0.7
Property Plant And Equipment Net	0.62	0.87	0.66	0.66	0.21	0.78	-0.92	0.66	0.59	0.7	0.74	0.49	0.84	0.88	0.84	0.68	-0.14	0.72		-0.27	0.44	0.6	0.73	0.31	0.72	0.99
Current Deferred Revenue	0.2	-0.27	0.09	0.17	0.49	-0.37	0.33	-0.19	0.2	0.06	0.03	-0.15	-0.15	-0.15	-0.09	0.1	0.74	0.14	-0.27		0.41	-0.54	-0.03	0.5	0.01	-0.28
Non Current Assets Total	0.93	0.58	0.79	0.8	0.85	0.4	-0.51	0.51	0.76	0.84	0.8	0.34	0.73	0.7	0.76	0.87	0.42	0.86	0.44	0.41		0.21	0.63	0.98	0.82	0.42
Non Currrent Assets Other	0.31	0.65	0.56	0.4	0.03	0.71	-0.74	0.74	0.08	0.33	0.45	0.32	0.57	0.69	0.58	0.35	-0.3	0.45	0.6	-0.54	0.21		0.73	0.08	0.43	0.67
Other Current Assets	0.68	0.84	0.8	0.71	0.4	0.84	-0.86	0.86	0.34	0.66	0.69	0.44	0.83	0.9	0.86	0.69	0.04	0.75	0.73	-0.03	0.63	0.73		0.52	0.76	0.79
Intangible Assets	0.86	0.46	0.68	0.71	0.85	0.28	-0.38	0.43	0.73	0.75	0.72	0.26	0.63	0.58	0.66	0.78	0.5	0.76	0.31	0.5	0.98	0.08	0.52		0.72	0.29
Short Term Investments	0.96	0.84	0.82	0.86	0.67	0.71	-0.8	0.71	0.74	0.98	0.92	0.52	0.92	0.89	0.91	0.98	0.04	0.92	0.72	0.01	0.82	0.43	0.76	0.72		0.72
Property Plant And Equipment Gross	0.6	0.89	0.65	0.66	0.2	0.83	-0.95	0.74	0.53	0.68	0.72	0.49	0.84	0.91	0.85	0.66	-0.14	0.7	0.99	-0.28	0.42	0.67	0.79	0.29	0.72

Click cells to compare fundamentals

Travere Therapeutics Account Relationship Matchups

Travere Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	604.8M	607.4M	776.6M	672.6M	788.9M	461.7M
Short Long Term Debt Total	204.9M	215.7M	262.0M	407.5M	404.8M	425.0M
Other Current Liab	68.8M	80.5M	84.9M	104.0M	119.3M	60.3M
Total Current Liabilities	95.4M	92.7M	124.1M	142.2M	177.9M	89.6M
Total Stockholder Equity	221.2M	211.2M	302.1M	42.9M	200.8M	168.0M
Net Debt	142.4M	130.6M	96.2M	345.8M	346.6M	363.9M
Retained Earnings	(416.4M)	(585.9M)	(766.0M)	(1.0B)	(1.1B)	(1.1B)
Accounts Payable	26.6M	12.1M	15.1M	17.3M	41.7M	43.8M
Cash	62.4M	84.8M	165.8M	61.7M	58.2M	58.0M
Cash And Short Term Investments	398.5M	361.6M	552.9M	450.2M	566.9M	284.6M
Common Stock Shares Outstanding	42.3M	47.5M	59.8M	63.8M	74.3M	45.7M
Liabilities And Stockholders Equity	604.8M	607.4M	776.6M	672.6M	788.9M	461.7M
Non Current Liabilities Total	288.2M	303.6M	350.4M	487.6M	410.2M	430.7M
Other Stockholder Equity	636.9M	798.0M	1.1B	1.1B	1.3B	1.4B
Total Liab	383.6M	396.2M	474.5M	629.7M	588.1M	617.5M
Total Current Assets	429.1M	410.4M	582.8M	486.4M	616.8M	316.3M
Short Term Debt	2.6M	357K	7.8M	8.9M	9.8M	9.4M
Property Plant And Equipment Net	2.9M	9.4M	34.3M	30.0M	25.5M	26.8M
Current Deferred Revenue	(2.6M)	(357K)	16.3M	12.0M	7.1M	11.3M
Non Current Assets Total	175.7M	197.0M	193.8M	186.1M	172.1M	169.6M
Non Currrent Assets Other	14.7M	33.5M	11.1M	11.1M	42.2M	44.3M
Other Current Assets	6.4M	8.1M	6.7M	15.0M	19.3M	20.3M
Intangible Assets	157.2M	153.2M	148.4M	145.0M	103.7M	140.4M
Short Term Investments	336.1M	276.8M	387.1M	388.6M	508.7M	288.4M
Property Plant And Equipment Gross	2.9M	9.4M	34.3M	30.0M	33.0M	34.6M
Accumulated Other Comprehensive Income	726K	(902K)	(562K)	(2.9M)	(1.5M)	(1.4M)
Net Receivables	18.0M	33.1M	15.9M	16.6M	21.2M	21.3M
Inventory	6.1M	7.6M	7.3M	6.9M	9.4M	6.0M
Other Liab	83.3M	59.9M	92.4M	84.5M	76.1M	67.7M
Net Tangible Assets	63.1M	57.1M	153.7M	(102.2M)	(92.0M)	(87.4M)
Other Assets	14.7M	7.8M	11.1M	36K	32.4K	30.8K
Long Term Debt	204.9M	215.3M	226.6M	375.5M	377.3M	257.7M
Net Invested Capital	426.1M	426.6M	528.7M	418.4M	578.1M	511.0M
Non Current Liabilities Other	83.3M	88.2M	20.4M	73.6M	8.5M	8.1M
Net Working Capital	333.6M	317.7M	458.7M	344.3M	438.9M	396.7M
Property Plant Equipment	2.9M	35.1M	11.1M	9.0M	10.4M	11.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Travere Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Ev To Free Cash Flow

Free Cash Flow Yield

Travere Therapeutics fundamental ratios Correlations

Travere Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Travere Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Travere Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.98	Total Assets
Short Term Investments	+ 0.98	Cash And Short Term Investments

Retained Earnings	- 0.97	Short Long Term Debt Total
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.95	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Net Debt
Non Current Liabilities Total	- 0.93	Retained Earnings